The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Waiting for a miracle m8, not worth buying more for me............
Thanks. What are you waiting for exactly? Or expecting/hoping
Will you avg down?
Hi bunsenburner123 I have been invested here for years mate.
Its a long waiting game at the moment.
You will need to read the RNS's and see the video's plus read all the posts here.
https://uk.finance.yahoo.com/news/apollon-formularies-plc-resignation-non-095000614.html
Hi Kenny, are you invested here? What’s going on here? Thanks
And spread 100.00%
Wonder what that was about.....................
Spread 4,900.00%
What’s their cash position like? Potential raise after the main deal fell through?
Was that Licensing deal for £100k the first time they generated revenue then?
If you read the recent announcements from the company, there appears to be the possibility of finally monetizing the various products they have developed and patented.
What’s going on here? Is it total sh it or is there value here?
Pleased with the outcome. It will be interesting to see whether the recent announced licencing agreements have any impact on the share price now that the deal is not going ahead with Global Hemp.
Dr Stephen D Barnhill, CEO and Chairman of Apollon Formularies, commented: "Whilst the Disposal to GHG has now been terminated, the Company continues to retain all of its Assets and the Company is well placed to continue to grow its business globally. We are extremely pleased with our recent Exclusive License Agreement with PureCann Pty Ltd, as announced 24 July 2023. PureCann has already reached impressive commercial milestones allowing us to immediately expand the "Apollon" Brand with our full medical product portfolio for multiple medical conditions into South Africa through their network of dispensaries as well as in their proposed treatment facilities." Dr Barnhill continued: "The Company is currently in discussions with additional companies in multiple countries also looking to license the Apollon intellectual property and products. We look forward to continuing to expand the Apollon brand into additional markets globally."
The Directors of the Company accept responsibility for the contents of this announcement.
For additional information, please visit www.apollon.org.uk or contact:
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the AQSE Growth Market, that is licenced to research, develop, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision, announces that the Company will not be proceeding with proposed deal with Global Hemp Group Inc. ("GHG") under the binding letter of intent ("LOI") released on the 12th of January 2023
As announced on 12 January 2023, under the terms of the binding LOI dated January 9, 2023, GHG acquired the exclusive perpetual license for North America (specifically, the United States, Canada. and Mexico) to certain Apollon Intellectual Property and proprietary technology, for US$250,000 and 10,000,000 common shares in GHG. On April 4, 2023 GHG announced that it completed its contractual payment obligations relating to the Exclusive Licensing Agreement for the patents and Intellectual Property ("IP") of Apollon. On March 21, 2023, GHG announced that the Company added additional exclusive licenses from Apollon for the countries of Israel, and the European Union (with extension to Morocco).
Apollon expects to benefit from the Licensing Fee revenues which shall equal 10% of gross sublicensing fees received by GHG. During the term of this License Agreement, GHG shall pay a quarterly licensing fee to Apollon, the payment of which shall be triggered when revenues are first generated from sublicensing activities. Payment of the Licensing Fee shall commence in the subsequent quarter as agreed to in the License Agreement dated January 19, 2023, emanating from all gross sublicensing fees received by GHG in North America (the United States, Canada, and Mexico), the European Union with extension to Morocco and Israel. In addition, under the LOI, a due diligence period was allowed and if both the Company and GHG were satisfied, GHG would have the exclusive option to acquire all the assets of Apollon, other than cash, cash equivalents, and receivables, for a payment of 771,191,266 GHG common shares at a deemed price of $0.015 per GHG common share, for a total consideration of C$11,567,869 ("Disposal"). The Disposal has been terminated by mutual consent.
Dr Stephen D Barnhill, CEO and Chairman of Apollon Formularies, commented: "Whilst the Disposal to GHG has now been terminated, the Company continues to retain all of its Assets and the Company is well placed to continue to grow its business globally. We are extremely pleased with our recent Exclusive License Agreement with PureCann Pty Ltd, as announced 24 July 2023. PureCann has already reached impressive commercial milestones allowing us to immediately expand the "Apollon" Brand with our full medical product portfolio for multiple medical conditions into South Africa through their network of dispensaries as well as in their proposed treatment facilities." Dr Barnhill continued:
Apollon Formularies Plc - Apollon grants an Exclusive Licence Agreement to PureCann, South Africa
https://uk.finance.yahoo.com/news/apollon-formularies-plc-apollon-grants-100000836.html
Thanks for the update m8, all the best Kenny......
Outlook
Looking ahead, we are optimistic about the future of Apollon Formularies. We remain committed to advancing our pipeline of innovative natural biologic products, expanding our global footprint, and delivering sustainable long-term growth. We continue to invest in research and development, patent protecting our discoveries, and leveraging cutting-edge artificial intelligence technologies and scientific advancements to develop breakthrough therapies that address unmet medical needs.
We are excited to have completed and filed the necessary national phase patent application through the PCT in the following territories: the US, Canada, Mexico, Israel, and the European Union with extension to Morocco and South Africa. The Group also has patent applications pending in Jamaica. These patent applications have resulted in significant upfront licencing fees and should continue to provide revenue to Apollon through product royalties. We continue to negotiate with additional potential licencees for additional expansion of our intellectual property rights and product sales globally.
We also look forward to the final decision from GHG on its due diligence.
Https://polaris.brighterir.com/public/apollon_formularies/news/rns/story/rgzm3zw
Https://polaris.brighterir.com/public/apollon_formularies/news/rns/story/x5voqpw
Extract
Apollon Formularies Plc
Apollon grants an Exclusive Licence Agreement to PureCann, South Africa
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, is pleased to announce that it has signed an Exclusive License Agreement with PureCann Pty Ltd. ("PureCann"), a South African based medical cannabis company, which will produce, and actively distribute the entire Apollon product range throughout their dispensary network currently being rolled out in South Africa. The license includes the rights to distribute Apollon proprietary medicinal products to the Southern African Development Community (SADC) and throughout the African continent where medical cannabis is legally available once the relevant export licenses have been secured by PureCann for these regions.
Transaction Highlights:
-- Apollon will receive a once off licensing fee of £100’000 as well as an
ongoing royalty of 6% of gross profit on sales by PureCann for the
entire term of the licence.
-- Apollon grants PureCann an Exclusive Licence which gives PureCann the
rights to Apollon’s Patent applications, Proprietary Formulations,
Patient Protocols and access to the technology relating to formulations
which showed successful cancer cell killing in the BIOENSIS pre-clinical
studies.
-- Apollon will benefit from brand exposure and sales royalties in
PureCann’s licensed medical cannabis dispensaries as well as PureCann’s
treatment facilities planning on being rolled out in Q4 of 2023.
-- Further Sub-Licence revenue will be applicable at a commercially
favourable split between Apollon and PureCann where PureCann are able to
enter into sub license agreements with the other nine African countries
where medicinal cannabis is legally available to patients in those
jurisdictions under a Sales and Distribution agreement along with
further jurisdictions which may legalise in the term of this licence
agreement.
-- Apollon will also benefit from crucial clinical data and royalties
generated from PureCann’s Treatment centre in Cape Town, South Africa in
the near future.
Anyone know if this is good value???
Yeh but it’s for like multiples of current mkt cap. I don’t get why it’s so cheap
The first part of the deal was for ten million shares. If they then proceed with second part, everything it’s 771 million shares of hemp.
So I’m assuming we get some, a % of the hemp shares as replacement? There not buying the company for cash their trading for their shares.
So is this any good then?
Do we get their shares, we get global hemp shares so we continue to trade, sometimes it’s done as they value the business higher, all done third week ish in April